Disease activity return after natalizumab cessation in multiple sclerosis

Area of Science:

• Neurology
• Immunology

Background:

• Natalizumab (NAT) is a monoclonal antibody for relapsing-remitting multiple sclerosis (MS).
• NAT demonstrates significant efficacy but its use is limited by risks.
• Key concerns include progressive multifocal leukencephalopathy (PML), neutralizing antibodies, and pregnancy.

Purpose of the Study:

• To review therapeutic strategies for preventing disease recurrence after natalizumab cessation.
• To analyze the implications and consequences of stopping NAT treatment.
• To emphasize the need for subsequent therapy post-NAT.

Main Methods:

• Review of clinical trial data.
• Analysis of case series.
• Evaluation of therapeutic strategies for managing NAT cessation.

Main Results:

• Disease activity often returns upon suspension or cessation of NAT.
• Evidence suggests various strategies can prevent or reduce this recurrence.
• Stopping NAT has significant implications requiring careful management.

Conclusions:

• The decision to discontinue NAT treatment requires careful consideration of risks and benefits.
• Subsequent therapy is crucial to mitigate the risk of disease recurrence after NAT cessation.
• Effective management strategies are needed to maintain disease control post-NAT.